Please check your internet connection and try again.
## Clobazam (Oral Formulation)
### Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. It is thought to exert its effects by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) in the central nervous system.
### Primary Indications
Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
### Adult Dosing
* **Initial dose:** 5 mg orally twice daily.
* **Titration:** Increase dose gradually based on response and tolerability.
* **Usual maintenance dose:** 10 mg orally twice daily.
* **Maximum dose:** 20 mg orally twice daily (40 mg/day).
### Pediatric Dosing (2 years and older)
* **Initial dose:** 5 mg orally twice daily.
* **Titration:** Increase dose gradually based on response and tolerability.
* **Usual maintenance dose:** 10 mg orally twice daily.
* **Maximum dose:** 20 mg orally twice daily (40 mg/day).
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustment guidelines are established, but consider starting at the lower end of the dosing range and titrating slowly.
* **Renal Impairment:** No specific dose adjustment guidelines are established, but monitor closely for adverse effects.
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic impairment.
### Adverse Effects
Common adverse effects include somnolence, drooling, constipation, decreased appetite, and vomiting. Serious adverse effects can include severe cutaneous reactions (e.g., Stevens-Johnson syndrome), respiratory depression, withdrawal symptoms, and suicidal ideation.
### Key Drug Interactions
* **CNS Depressants:** Additive effects with alcohol, opioids, other benzodiazepines, sedatives, and hypnotics can lead to profound sedation, respiratory depression, and coma.
* **CYP2C19 Substrates/Inhibitors:** Clobazam is a substrate of CYP2C19. Fluconazole (a strong CYP2C19 inhibitor) can increase clobazam concentrations. Omeprazole and esomeprazole (CYP2C19 substrates) may have altered efficacy or toxicity due to clobazam.
* **Strong CYP3A4 Inducers:** May decrease clobazam concentrations.
### Monitoring
* Monitor for therapeutic response and adverse effects, particularly somnolence and changes in behavior.
* Monitor for signs and symptoms of severe cutaneous reactions.
* Monitor for signs of withdrawal if treatment is discontinued abruptly, especially after long-term use or high doses.
* Monitor for suicidal ideation and behavior.
### Clinical Pearls
* Clobazam has a longer half-life compared to other benzodiazepines, which may allow for less frequent dosing.
* Tapering of the dose is recommended upon discontinuation to avoid withdrawal symptoms.
* The risk of serious skin reactions (SJS/TEN) is a significant concern. Patients and caregivers should be educated to discontinue clobazam immediately and seek medical attention at the first sign of a rash.
***
**Disclaimer:** This information is intended for clinical use and does not replace professional judgment. Always consult the most current prescribing information and relevant literature for complete details and to ensure patient-specific appropriateness of care.
